U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS
This repository is under review for potential modification in compliance with Administration directives.

Details

Stereochemistry ABSOLUTE
Molecular Formula C19H32N2O5.C4H11N.H2O
Molecular Weight 459.6199
Optical Activity UNSPECIFIED
Defined Stereocenters 5 / 5
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of PERINDOPRIL ERBUMINE MONOHYDRATE

SMILES

O.CC(C)(C)N.CCC[C@H](N[C@@H](C)C(=O)N1[C@H]2CCCC[C@H]2C[C@H]1C(O)=O)C(=O)OCC

InChI

InChIKey=AAQKIIDLRYLALW-MXLIJYGISA-N
InChI=1S/C19H32N2O5.C4H11N.H2O/c1-4-8-14(19(25)26-5-2)20-12(3)17(22)21-15-10-7-6-9-13(15)11-16(21)18(23)24;1-4(2,3)5;/h12-16,20H,4-11H2,1-3H3,(H,23,24);5H2,1-3H3;1H2/t12-,13-,14-,15-,16-;;/m0../s1

HIDE SMILES / InChI
Molecular Formula C4H11N
Molecular Weight 73.1368
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE
Molecular Formula C19H32N2O5
Molecular Weight 368.4678
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 5 / 5
E/Z Centers 0
Optical Activity UNSPECIFIED
Molecular Formula H2O
Molecular Weight 18.0153
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment: description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/1718688

Perindoprilat is a metabolite of perindopril. Perindopril is a long-acting angiotensin converting enzyme (ACE) inhibitor and it is used to treat high blood pressure, heart failure or stable coronary artery disease. Perindopril is designed to allow oral administration as perindoprilat is poorly absorbed from the gastrointestinal tract.

CNS Activity

CNS Active
4002
Curator's Comment: Known to be CNS active in rats. Human data not available.

Originator

Approval Year

1993
138
Targets

Targets

Primary TargetPharmacologyConditionPotency
Inhibitor
8504
 1.05 nM [IC50]
Inhibitor
8504
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Approved
8583
ACEON

Approved Use

Perindopril erbumine tablets are indicated for treatment of patients with stable coronary artery disease to reduce the risk of cardiovascular mortality or nonfatal myocardial infarction. Perindopril erbumine tablets can be used with conventional treatment for management of coronary artery disease, such as antiplatelet, antihypertensive or lipid-lowering therapy.

Launch Date

1993
Primary
Approved
8583
ACEON

Approved Use

Perindopril erbumine tablets are indicated for the treatment of patients with essential hypertension. Perindopril erbumine tablets may be used alone or given with other classes of antihypertensives, especially thiazide diuretics.

Launch Date

1993
Palliative
Not Provided
511
Unknown

Approved Use

Unknown
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
83.83 ng/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/21650082
4 mg single, oral
dose: 4 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
PERINDOPRIL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
3.54 ng/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/21650082
4 mg single, oral
dose: 4 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
PERINDOPRILAT plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
130 ng × h/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/21650082
4 mg single, oral
dose: 4 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
PERINDOPRIL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
170.61 ng × h/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/21650082
4 mg single, oral
dose: 4 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
PERINDOPRILAT plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
1.05 h
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/21650082
4 mg single, oral
dose: 4 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
PERINDOPRIL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
38.01 h
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/21650082
4 mg single, oral
dose: 4 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
PERINDOPRILAT plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
40%
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/21650082
4 mg single, oral
dose: 4 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
PERINDOPRIL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
80%
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/21650082
4 mg single, oral
dose: 4 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
PERINDOPRILAT plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
Doses

Doses

DosePopulationAdverse events​
4 mg 1 times / day steady, oral
Recommended
Dose: 4 mg, 1 times / day
Route: oral
Route: steady
Dose: 4 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/12076191/
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: unknown
Sources:
https://pubmed.ncbi.nlm.nih.gov/12076191/
Disc. AE: Cough...
AEs leading to
discontinuation/dose reduction:
Cough (2.8%)
Sources:
https://pubmed.ncbi.nlm.nih.gov/12076191/
AEs

AEs

AESignificanceDosePopulation
Cough 2.8%
Disc. AE
4 mg 1 times / day steady, oral
Recommended
Dose: 4 mg, 1 times / day
Route: oral
Route: steady
Dose: 4 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/12076191/
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: unknown
Sources:
https://pubmed.ncbi.nlm.nih.gov/12076191/
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG

OverviewOther

Other InhibitorOther SubstrateOther Inducer
CYP2J2
33
UGT
219

CYP
303
CYP
74
Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
CYP
150
 no
CYP2J2
36
 no
Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
CYP
303
 no
UGT
219
 yes
Sourcing

Sourcing

Vendor/AggregatorIDURL
ChEBI
CHEBI:132041
https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:132041
ChemicalBook
CB0240343
https://www.chemicalbook.com/ChemicalProductProperty_EN_CB0240343
eMolecules
36754394
https://www.emolecules.com/cgi-bin/more?vid=36754394
MolPort
MolPort-006-395-652
https://www.molport.com/shop/molecule-link/MolPort-006-395-652
ZINC
ZINC000004217270
http://zinc15.docking.org/substances/ZINC000004217270
PubMed

PubMed

TitleDatePubMed
[The effect of amlodipine, nifedipine and perindopril on insulin sensitivity and blood lipid of patients with essential hypertension].
1998 Mar
ACE DD genotype is more susceptible than ACE II and ID genotypes to the antiproteinuric effect of ACE inhibitors in patients with proteinuric non-insulin-dependent diabetes mellitus.
2000 Oct
[The comparison of clinical effectiveness of perindopril and acebutolol in the primary hypertension treatment].
2001
Indapamide plus perindopril--simpler treatment, better compliance.
2001 Apr-May
Anglo-Scandinavian Cardiac Outcomes Trial: a brief history, rationale and outline protocol.
2001 Aug
Persistent cardiovascular effects of chronic renin-angiotensin system inhibition following withdrawal in adult spontaneously hypertensive rats.
2001 Aug
Comparison of spectrophotometric and an LC method for the determination perindopril and indapamide in pharmaceutical formulations.
2001 Aug
The lowering of blood pressure after stroke.
2001 Dec 8
The lowering of blood pressure after stroke.
2001 Dec 8
The lowering of blood pressure after stroke.
2001 Dec 8
The lowering of blood pressure after stroke.
2001 Dec 8
The lowering of blood pressure after stroke.
2001 Dec 8
Inhibition of neointima by angiotensin-converting enzyme inhibitor in porcine coronary artery balloon-injury model.
2001 Feb
Hyperoxia/normoxia-driven retinal angiogenesis in mice: a role for angiotensin II.
2001 Feb
Assessment of perindopril's efficacy on arterial distensibility in mild to moderate hypertension.
2001 Jul
Renoprotective and anti-hypertensive effects of combined valsartan and perindopril in progressive diabetic nephropathy in the transgenic (mRen-2)27 rat.
2001 Jul
Rationale, design, methods and baseline demography of participants of the Anglo-Scandinavian Cardiac Outcomes Trial. ASCOT investigators.
2001 Jun
Coversyl plus--when monotherapy is not enough.
2001 Jun-Jul
The EUROPA trial: design, baseline demography and status of the substudies.
2001 Mar
Elimination of early rehospitalization in a randomized, controlled trial of multidisciplinary care in a high-risk, elderly heart failure population: the potential contributions of specialist care, clinical stability and optimal angiotensin-converting enzyme inhibitor dose at discharge.
2001 Mar
Pulmonary vascular remodelling in hypoxic rats: effects of amlodipine, alone and with perindopril.
2001 Mar 23
Salt sensitivity in genetically hypertensive rats of the Lyon strain.
2001 May
[Clinical study of the month. Secondary prevention of cerebrovascular accident with perindopril: the PROGRESS study].
2001 Nov
Effect of angiotensin-converting enzyme inhibition on renal filtration surface area in hypertensive rats.
2001 Nov
Angiotensin-converting enzyme inhibition improves defective angiogenesis in the ischemic limb of spontaneously hypertensive rats.
2001 Nov
Effects of combined administration of ACE inhibitor and angiotensin II receptor antagonist are prevented by a high NaCl intake.
2001 Nov
Improvement in blood pressure, arterial stiffness and wave reflections with a very-low-dose perindopril/indapamide combination in hypertensive patient: a comparison with atenolol.
2001 Oct
Effects of perindopril on cardiovascular remodeling.
2001 Oct 4
Perindopril treatment for congestive heart failure.
2001 Oct 4
Restenotic process and DD genotype after angiotensin-converting enzyme inhibitor treatment.
2001 Sep 1
Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack.
2001 Sep 29
Blood-pressure lowering for the secondary prevention of stroke.
2001 Sep 29
Identification and determination of selected medicines reducing hypertension by densitometric and gas chromatographic methods.
2001 Sep-Oct
Detection of coronary microvascular disease by means of cardiac scintigraphy.
2002 Feb
Combined therapy with indapamide and perindopril but not perindopril alone reduced the risk for recurrent stroke.
2002 Mar-Apr
Patents

Patents

07279595
6
08686161
7
20060063941
8
20070071838
8
20100298400
6
7351840
8
7858611
6
8470869
6
JP2002535367A
25
JP2002536332A
39
JP2008019214A
6
JP2011506455A
52
JP4705912B2
48
US4508729
6
WO2004046172A1
8
WO2007017893A2
6
WO2007017893A3
6
WO2007017893B1
6
WO2007017894A2
6
WO2007058634A1
6
WO2007058634B1
6
WO2007092758A2
6
WO2008114270A1
6
WO2008150245A2
6
WO2009000909A2
6
WO2012044189A1
6

Sample Use Guides

In Vivo Use Guide
Unknown
Route of Administration: Unknown
In Vitro Use Guide
Unknown
Substance Class Chemical
Created
by admin
on Mon Mar 31 18:40:47 GMT 2025
Edited
by admin
on Mon Mar 31 18:40:47 GMT 2025
Record UNII
DV54578K4P
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
PERINDOPRIL ERBUMINE MONOHYDRATE
Common Name English
1H-INDOLE-2-CARBOXYLIC ACID, 1-((2S)-2-(((1S)-1-(ETHOXYCARBONYL)BUTYL)AMINO)-1-OXOPROPYL)OCTAHYDRO-, (2S,3AS,7AS)-, COMPD. WITH 2-METHYL-2-PROPANAMINE, HYDRATE (1:1:1)
Preferred Name English
Code System Code Type Description
SMS_ID
100000130680
Created by admin on Mon Mar 31 18:40:47 GMT 2025 , Edited by admin on Mon Mar 31 18:40:47 GMT 2025
PRIMARY
PUBCHEM
9847044
Created by admin on Mon Mar 31 18:40:47 GMT 2025 , Edited by admin on Mon Mar 31 18:40:47 GMT 2025
PRIMARY
CAS
690267-97-1
Created by admin on Mon Mar 31 18:40:47 GMT 2025 , Edited by admin on Mon Mar 31 18:40:47 GMT 2025
PRIMARY
FDA UNII
DV54578K4P
Created by admin on Mon Mar 31 18:40:47 GMT 2025 , Edited by admin on Mon Mar 31 18:40:47 GMT 2025
PRIMARY
Related Record Type Details
Structure of Erbumine
PARENT -> SALT/SOLVATE
Structure of PERINDOPRIL ERBUMINE
ANHYDROUS->SOLVATE
Structure of PERINDOPRIL
PARENT -> SALT/SOLVATE
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966